

NOV. 7. 2005 10:03AM AVENTIS US PAT DEPT
TO: US CENTRALIZED USPTO

NO. 9591 P. 1/2

RECEIVED
CENTRAL FAX CENTER

NOV 07 2005

PTO/SB/21 (08-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

2

Application Number

10/088,138

Filing Date

March 15, 2002

First Named Inventor

Saliha MOUSSAOUI-MRABET et al.

Art Unit

1632

Examiner Name

FALK, Anne Marie

Attorney Docket Number

ST99040 US PCT

ENCLOSURES (Check all that apply)

- Fee Transmittal Form
 Fee Attached
 Amendment/Reply
 After Final
 Affidavits/declaration(s)
 Extension of Time Request
 Express Abandonment Request
 Information Disclosure Statement
 Certified Copy of Priority Document(s)
 Reply to Missing Parts/ Incomplete Application
 Reply to Missing Parts under 37 CFR 1.52 or 1.53

- Drawing(s)
 Licensing-related Papers
 Petition
 Petition to Convert to a Provisional Application
 Power of Attorney, Revocation
 Change of Correspondence Address
 Terminal Disclaimer
 Request for Refund
 CD, Number of CD(s) _____
 Landscape Table on CD(s)

- After Allowance Communication to TC
 Appeal Communication to Board of Appeals and Interferences
 Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
 Proprietary Information
 Status Letter
 Other Enclosure(s) (please identify below):


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

sanofi-aventis

Signature



Printed name

Karen I. KRUPEN

Date

November 07, 2005


Reg. No.

34,647

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 : Total No. of Pages Transmitted: 2)

Signature



Typed or printed name

Delia Coughlin

Date

November 07, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV. 7, 2005 10:03AM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 9591 P. 2/2

PATENT

NOV 07 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: A. Falk

In re Application of
Moussaoui-Mrabet et al.

Art Unit: 1632

Application No.: 10/088,138

Filed: November 23, 2002

Title: NOVEL ANIMAL MODEL OF
ALZHEIMER DISEASE WITH
AMYLOID PLAQUES AND
MITOCHONDRIAL DYSFUNCTIONS

Telefacsimile Certificate

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

Nov. 7, 2005

Date of Transmission

Signature *Karen Krupen*

RESPONSE TO OFFICE COMMUNICATION

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication mailed October 5, 2005 in the above-referenced application, Applicants elect Group I, claims 1-10 and 13, drawn to non-human transgenic animal models of Alzheimer's disease to be prosecuted.

The Commissioner is authorized to charge any additional fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,

Karen Krupen
Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-4658
Telefax: 908-231-2626

Docket No. ST99040 US PCT